Abstract:Abstract.In recent years baseline predictors of Peg-INF response have been identified, one of the host factors may be include: genetic polymorphism IFNL-3 (IL-28B). The aim of the study. In recent years baseline predictors of Peg-INF response have been identi We investigated the effect of IFNL-3 polymorphism (SNP 12979860, SNP rs8099917) fied, one of the host on HBV DNA kinetics, qHBsAg, SVR rate and HBsAg clearance. as one of the positive prognostic factors of SBB induction. Methods. We investigated the effect of IFNL-3 polymorphism (SNP 12979860, SNP rs8099917) on the kinetics of HBV DNA, qHBsAg, the rate of SVR and HBsAg clearance. 108 patients with HBeAg-negative hepatitis B, genotype D were enrolled into the study. Results. Of 46 patients with CC SNP 12979860, a decline in the concentration of HBsAg>0.5 log10 at 12 weeks of treatment, was noticed in 23 (50.0%) persons in the group of 61 patients, and in 14 (23.0%) with CT alleles (OR=3.36, 95% CI 1.35–8.4, P<0.005). SVR was achieved in 19 (41, 3%) and 12 (19.7%), respectively (OR=3.35, 95% CI 1.12–7.5, P 2 log10 at week 12 was observed in 42 (91.3%), and in 61 patients with CT — in 54 (88.5%) (OR=1.36,CI 0.32–6.75, P=0,0639). At 24 weeks of therapy, the decline in HBV DNA by 2 log10 in the group of patients with CC was detected in 46 (100%) and in those with CT in 61 patients (100%). SVR was achieved in 20 persons (43.5%) and in 11 (18%), respectively (OR=3.5, 95% CI 1.34–9.31, P 0.5 log10 at week 12 was achieved in 27 (42.8%), in the TG group (n=45) — only in 5 (11.1%) (OR=6.0, 95% CI 1.96–21.74, P<0.001). SVR was documented in 24 (38.1%) and 7 (15.6%), respectively (OR=3.34, 95% CI 1.20–10.19, P<0.01). At 12 weeks of therapy in the group with TT alleles, a 2 log10 decline in HBV DNA was observed in 58 individuals (92.0%), in the group with TG — in 40 (88.8%) (OR=1.45, 95% CI 0.31–6.73 P=0.575). At week 24: in TT — 63 patients (100.0%) and in TG — 45 patients (100.0%). SVR was achieved in 23 (36.5%) and 8 (17.7%), respectively (OR=2.66, 95% CI 0.99–7.7, P<0.05). Conclusion. The presented study demonstrates that favorable genetic polymorphism IFNL-3 (SNP 12979860 and SNP rs8099917) is one of the most significant baseline positive predictive factors on SVR induction. Keywords HBeAg-negative chronic hepatitis B, peginterferon, IFNL-3 (IL-28B) polymorphism, sustained virological response, HBsAg.

IFIT1 Polymorphisms Predict Interferon-Α Treatment Efficiency for Hepatitis B Virus Infection.

A Functional SNP of Interferon-Γ Gene is Important for Interferon-Α-induced and Spontaneous Recovery from Hepatitis C Virus Infection

Association of Single Nucleotide Polymorphisms in Interferon Signaling Pathway Genes and Interferon-Stimulated Genes with the Response to Interferon Therapy for Chronic Hepatitis C

Evaluation of Susceptibility Locus for Response to Interferon-Α Based Therapy in Chronic Hepatitis B Patients in Chinese

KIR3DS1/HLA-B Bw4-80Ile Genotype is Correlated with the IFN-α Therapy Response in Hepatitis B E Antigen-Positive Chronic Hepatitis B

Polymorphisms in IRG1 gene associated with immune responses to hepatitis B vaccination in a Chinese Han population and function to restrain the HBV life cycle

Human leukocyte antigen class I and class II genes polymorphisms might be associated with interferon α therapy efficiency of chronic hepatitis B.

IMPACT OF IFNL-3 (IL-28B) POLYMORPHISM ON THE KINETICS OF HBV DNA AND QHBSAG AND HBSAG CLEARANCE DURING THERAPY WITH PEGINTERFERON α-2A IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B, GENOTYPE D

Association of IFNL3/IFNL4 Polymorphisms with Efficacy of Highly Active Antiretroviral Therapy in Patients with HIV-1 Infection

Association of Rs2111485 and Rs1990760 Polymorphisms of Interferon Induced with Helicase C Domain 1 Gene with Hepatitis C Virus Clearance in Chinese Han Population.

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients

No Association Between IFNL3 (IL28B) Genotype and Response to Peginterferon Alfa-2A in HBeAg-positive or -Negative Chronic Hepatitis B.

Genetic Variation in STAT4 Predicts Response to Interferon‐α Therapy for Hepatitis B E Antigen‐positive Chronic Hepatitis B

A Potential Functional Cure In Chinese Hbeag-Negative Chronic Hepatitis B Patients Treated With Peg-Interferon Alpha-2a

Polymorphisms of Type I Interferon Receptor 1 Promoter and Their Effects on Chronic Hepatitis B Virus Infection.

Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China

Role of Functional IFNL4, IFNLR1, IFNA, IFNAR2 Polymorphisms in Hepatitis B virus-related liver disease in Han Chinese population.

Treated with Interferon and the Gene Polymorphism of CGRP and Its Receptor.

Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B.

Association of Interferon-Gamma Gene Haplotype in the Chinese Population with Hepatitis B Virus Infection.

Genetic Variation in FCER1A Predicts Peginterferon Alfa‐2a‐induced Hepatitis B Surface Antigen Clearance in East Asian Patients with Chronic Hepatitis B